{"id":472530,"date":"2021-04-07T07:33:18","date_gmt":"2021-04-07T11:33:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=472530"},"modified":"2021-04-07T07:33:18","modified_gmt":"2021-04-07T11:33:18","slug":"olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\/","title":{"rendered":"Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference"},"content":{"rendered":"
\n

SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cOlema Oncology,\u201d NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers, today announced Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference on Thursday, April 15 at 12 p.m. ET. The fireside chat will be moderated by Arlinda Lee, Ph.D., Managing Director, Biotechnology Analyst at Canaccord Genuity.<\/p>\n

A live webcast of the event will be accessible in the Investors & Media<\/a> section of Olema\u2019s website. A replay of the webcast will be available.<\/p>\n

\n About Olema Oncology<\/strong>
\n
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers. Olema\u2019s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1\/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco.<\/p>\n

Investor Contact:
ir@olema.com<\/u><\/a><\/p>\n

Media Contact:
Sheryl Seapy, Real Chemistry
sseapy@realchemistry.com<\/a>
949-903-4750<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cOlema Oncology,\u201d NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers, today announced Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference on Thursday, April 15 at 12 p.m. ET. The fireside chat will be moderated by Arlinda Lee, Ph.D., Managing Director, Biotechnology Analyst at Canaccord Genuity. A live webcast of the event will be accessible in the Investors & Media section of Olema\u2019s website. A replay of the webcast will be available. About Olema Oncology Olema Oncology is a clinical-stage … <\/p>\n

Continue reading “Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-472530","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOlema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cOlema Oncology,\u201d NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers, today announced Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference on Thursday, April 15 at 12 p.m. ET. The fireside chat will be moderated by Arlinda Lee, Ph.D., Managing Director, Biotechnology Analyst at Canaccord Genuity. A live webcast of the event will be accessible in the Investors & Media section of Olema\u2019s website. A replay of the webcast will be available. About Olema Oncology Olema Oncology is a clinical-stage … Continue reading "Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-07T11:33:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjY5MiM0MTA5MjE4IzIyMDM1MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference\",\"datePublished\":\"2021-04-07T11:33:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\\\/\"},\"wordCount\":238,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMjY5MiM0MTA5MjE4IzIyMDM1MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\\\/\",\"name\":\"Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMjY5MiM0MTA5MjE4IzIyMDM1MTU=\",\"datePublished\":\"2021-04-07T11:33:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMjY5MiM0MTA5MjE4IzIyMDM1MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMjY5MiM0MTA5MjE4IzIyMDM1MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference - Market Newsdesk","og_description":"SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cOlema Oncology,\u201d NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers, today announced Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference on Thursday, April 15 at 12 p.m. ET. The fireside chat will be moderated by Arlinda Lee, Ph.D., Managing Director, Biotechnology Analyst at Canaccord Genuity. A live webcast of the event will be accessible in the Investors & Media section of Olema\u2019s website. A replay of the webcast will be available. About Olema Oncology Olema Oncology is a clinical-stage … Continue reading \"Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-07T11:33:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjY5MiM0MTA5MjE4IzIyMDM1MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference","datePublished":"2021-04-07T11:33:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\/"},"wordCount":238,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjY5MiM0MTA5MjE4IzIyMDM1MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\/","name":"Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjY5MiM0MTA5MjE4IzIyMDM1MTU=","datePublished":"2021-04-07T11:33:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjY5MiM0MTA5MjE4IzIyMDM1MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjY5MiM0MTA5MjE4IzIyMDM1MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-the-canaccord-genuity-horizons-in-oncology-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/472530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=472530"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/472530\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=472530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=472530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=472530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}